Asked by: Lord Kempsell (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they will take to ensure equity and quality in care and support across the entire cancer pathway, including (1) fairness and equity in diagnostics, (2) on time treatment, and (3) patients being offered conversations about the additional care and support they may need.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is taking steps to ensure equity and quality in care and support for patients is available across the entire cancer pathway. Reducing inequalities and variation in cancer diagnosis and treatment are a priority for the Government, as is increasing early cancer diagnosis, as this is a key contributor to reducing cancer health inequalities. The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. As part of this, we are increasing diagnostic capacity by rolling out community diagnostic centres across England, with capacity prioritised for cancer checks. Additionally, and as outlined in the 2024/25 NHS England Planning Guidance, NHS England is providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.
The Department's ministers and officials frequently meet with key stakeholders within the cancer community, including discussions on support for patients and their families. The National Health Service provides personalised cancer care and support plans, to support both patients and their families at all stages of their cancer journey. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support.
General practice surgeries also conduct cancer care reviews at regular intervals after cancer diagnosis, to offer support with any needs patients may have. This includes providing access to other specialist-led services who work alongside patients’ medical teams, to support patients and their families, such as counsellors, rehabilitation specialists, or social prescribers, who can connect you to community groups or services for more support.
NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities in England are met, including for cancer patients. NHS England provides access to a personal health budget, which is an amount of NHS money that is allocated to support the health and wellbeing needs of a patient, if eligible.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they plan to support NHS England’s pilot to reduce the faecal immunochemical test threshold for the Bowel Cancer Screening Programme from 120µg/g to 80µg/g; and whether they have had discussions with NHS England regarding geographical areas for the pilot.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
We are committed to improving the NHS Bowel Screening programme, and welcome NHS England’s plans for pilot areas, which will reduce the faecal immunochemical test (FIT) down to 80µg/g. NHS England plans to publish an Expression of Interest to give all bowel screening services, and their partner symptomatic endoscopy providers, an opportunity to submit their interest in becoming a FIT@80 pilot site. These pilot sites are planned to be selected and launched later in 2024/25, and attention will be paid to ensure there is regional variation across the pilot sites selected.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Royal College of Radiologists report Clinical Radiology Workforce Census 2022, published on 8 June 2023, what steps they will take to address the shortfall in clinical oncologists in England.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Long Term Workforce Plan (LTWP) sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years. It will put the workforce on a sustainable footing for the long term.
We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010.
Regarding clinical oncology specifically, as of January 2024, there are currently over 1,600 FTE doctors working in the speciality of clinical oncology in NHS trusts and other core organisations in England. This is 2.2% more than last year, 27.7% more than 2019, and 66.5% more than in 2010. This includes over 900 FTE consultants. This is 5.1% more than last year, 22.0% more than in 2019, and 80.2% more than in 2010.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to (1) the recent Royal College of Radiologists’ Radiotherapy Briefing, published in May, and (2) the HERO (Health Economics in Radiation Oncology) report by the UK Radiotherapy Board, published on 2 May, what is their current assessment of the state of radiotherapy services in England.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
According to the latest data, of those 10,328 cancer patients referred for first or subsequent treatment for radiotherapy in March 2024, 89.7% were treated within 31 days. Since 2016, there has been significant investment in radiotherapy equipment, so that every radiotherapy provider had access to modern, cutting-edge radiotherapy equipment, enabling the rollout of new techniques like stereotactic ablative radiotherapy. The total central investment made between 2016 and 2021 was £162 million, and enabled the replacement or upgrade of approximately 100 radiotherapy treatment machines. This is investment on top of that committed by National Health Service trusts, either from their own capital budgets or via donations.
From April 2022, the responsibility for investing in new radiotherapy machines sits with local systems. As outlined in the 2024/25 NHS Planning Guidance, NHS England is providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer. This is supported by the 2021 Spending Review, which set aside £12 billion in operational capital for the NHS.
The Department is working closely with NHS England to make sure we have the right workforce with the right skills up and down the country. We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what progress they have made towards ensuring that people with cancer who require radiotherapy treatment can start treatment within their target of 31 days.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
We are seeing continued high levels of urgent cancer referrals, with over 12,000 urgent referrals seen for suspected cancer per working day in March 2024, compared to approximately 9,000 in March 2019. In March 2023, 89.7% of patients received a first or subsequent radiotherapy treatment within 31 days of a decision to treat, which is 0.6% higher than last year. From March 2023/24, 127,336 people received a first or subsequent radiotherapy treatment, which is 1,359 more than the previous year.
The Government continues to work with NHS England on implementing the Delivery plan for tackling the COVID-19 backlog of elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity.
We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010. This includes over 8,100 FTE consultants in January 2024, an increase of over 3,300, or 69.6% since January 2010.
Since 2016, the Department has invested £162 million into cutting-edge radiotherapy equipment to replace or upgrade more than 100 radiotherapy treatment machines, so we can deliver the best possible outcomes for patients. From April 2022, the responsibility for investing in new radiotherapy machines sits with local systems.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to meet their target of 96 per cent of cancer patients receiving treatment within 31 days of a decision to treat.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Tackling cancer is a key priority for the Government. Ministers and officials continue to work closely with NHS England to increase positive outcomes for all cancer types. The Government has allocated an additional £8 billion across this Spending Review period, to increase capacity and support elective recovery.
As outlined in the 2024/25 NHS Planning Guidance, NHS England are providing over £266 million in cancer service development funding to Cancer Alliances to support delivery of the operational priorities for cancer, increasing and prioritising diagnostic and treatment capacity.
We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7%, since January 2010. This includes over 8,100 FTE consultants in January 2024, an increase of over 3,300, or 69.6%, since January 2010.
Asked by: Alexander Stafford (Conservative - Rother Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an estimate of the annual cost to the NHS of pipe smoking.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Tobacco is responsible for approximately 80,000 deaths a year in the United Kingdom, and causes approximately one in four UK cancer deaths. It also costs our country £21.8 billion a year and puts a huge burden on the National Health Service. Latest estimates from Action on Smoking and Health put the cost of smoking to the NHS and social care at £3 billion a year.
All smoked tobacco is extremely harmful, including pipe smoking. Smoking is the main driver for conditions such as lung cancer and severe chronic obstructive pulmonary disease, and is a major factor for others such as premature cardiovascular disease.
Data from the Office for Health Improvement and Disparities Smoking Profile showed that in 2019/20 there were an estimated 448,031 smoking attributable hospital admissions, but we cannot differentiate by the type of tobacco. As such, the Department does not hold data on the annual costs to the NHS of pipe smoking, nor data on the number of hospital admissions for issues related to pipe smoking in the last 12 months, five years, or 20 years.
Asked by: Alexander Stafford (Conservative - Rother Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an estimate of the number of hospital admissions for issues related to pipe smoking in the last (a) 12 months, (b) five years and (c) 20 years.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Tobacco is responsible for approximately 80,000 deaths a year in the United Kingdom, and causes approximately one in four UK cancer deaths. It also costs our country £21.8 billion a year and puts a huge burden on the National Health Service. Latest estimates from Action on Smoking and Health put the cost of smoking to the NHS and social care at £3 billion a year.
All smoked tobacco is extremely harmful, including pipe smoking. Smoking is the main driver for conditions such as lung cancer and severe chronic obstructive pulmonary disease, and is a major factor for others such as premature cardiovascular disease.
Data from the Office for Health Improvement and Disparities Smoking Profile showed that in 2019/20 there were an estimated 448,031 smoking attributable hospital admissions, but we cannot differentiate by the type of tobacco. As such, the Department does not hold data on the annual costs to the NHS of pipe smoking, nor data on the number of hospital admissions for issues related to pipe smoking in the last 12 months, five years, or 20 years.
Asked by: Lord Sikka (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many of the 40 new hospitals confirmed by the then Prime Minister on 2 October 2020 have been completed and are operational.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The New Hospital Programme has opened six hospitals, listed as follows:
- the Northern Centre for Cancer Care, for the North Cumbria Integrated Care NHS Foundation Trust;
- the Royal Liverpool Hospital, for the Liverpool University Hospitals NHS Foundation Trust;
- stage 1 of the 3Ts Hospital, for the Brighton and Sussex University Hospitals NHS Trust;
- the Northgate Hospital and Ferndene Hospital, specifically phase 1 and phase 2 of the Care Environment Development and Re-provision Programme, for the Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust;
- the Dyson Cancer Centre, for the Royal United Hospitals Bath NHS Foundation Trust; and
- the Greater Manchester Major Trauma Centre, for the Northern Care Alliance NHS Foundation Trust.
Two more hospitals are due to open this financial year, listed as follows:
- the Midland Metropolitan University Hospital, for Sandwell and West Birmingham NHS Trust; and
- the National Rehabilitation Centre, for Nottingham University Hospitals NHS Trust.
Asked by: Stella Creasy (Labour (Co-op) - Walthamstow)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that patients taking pancreatic enzymes continue to receive them.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are aware of supply issues with three pancreatic enzyme replacement therapies: Creon 10000 gastro-resistant capsules; Creon 25000 gastro-resistant capsules; and Nutrizym 22 gastro-resistant capsules. We understand that these are due to limited availability of active pharmaceutical ingredients, and manufacturing constraints in producing the volumes required to meet demand. The Department has issued guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products, to ask that they expedite deliveries and increase production forecasts, and to confirm that they are taking action to address the root causes of the issues, to ensure continuity of supply. We are also working with specialist importers to source unlicensed imports from abroad.
Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.